Your browser doesn't support javascript.
loading
Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration.
Witt, W; Maass, B; Baldus, B; Hildebrand, M; Donner, P; Schleuning, W D.
Afiliação
  • Witt W; Department of Cardiovascular Pharmacology, Research Laboratories of Schering AG, Berlin, Germany.
Circulation ; 90(1): 421-6, 1994 Jul.
Article em En | MEDLINE | ID: mdl-8026028
ABSTRACT

BACKGROUND:

DSPA (Desmodus salivary plasminogen activator) is a new thrombolytic agent corresponding to a natural plasminogen activator discovered in the saliva of the vampire bat Desmodus rotundus. Compared with tissue plasminogen activator (TPA), DSPA, produced in a recombinant cell line, is more fibrin cofactor dependent than TPA. METHODS AND

RESULTS:

The thrombolytic properties of DSPA and TPA were compared in a canine model of copper coil-induced coronary thrombosis. All dogs received heparin 200 IU/kg IV and SC. Whereas controls did not reperfuse within 180 minutes (none of six), intravenous bolus administration of DSPA at 25, 50, and 100 micrograms/kg resulted in a 100% incidence (6 of 6) of recanalization within 37, 23, and 18 minutes, respectively. TPA at 63 and 125 micrograms/kg reopened the coronaries in 33% (two of six) and 50% (three of six) of cases within 40 minutes. Eighty-three percent (5 of 6) of the arteries were still patent 3 hours after 50 and 100 micrograms/kg DSPA, whereas only 20% (one of five) of all coronaries originally recanalized with both doses of TPA were still open at 3 hours. Plasma levels of alpha 2-antiplasmin decreased significantly only with 125 micrograms/kg TPA. The clearance of DSPA (2.3 to 3.5 mL.min-1.kg-1) was lower compared with TPA (11.4 to 20 mL.min-1.kg-1) due to a prolonged terminal half-life.

CONCLUSIONS:

In a canine coronary thrombosis model, DSPA exhibited higher potency and recanalized coronary arteries faster and with a lower incidence of reocclusion than TPA. Its properties may translate into a higher efficacy in patients compared with available thrombolytic agents. The long half-life of DSPA may allow for single bolus administration in the treatment of acute myocardial infarction.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Trombose Coronária / Ativadores de Plasminogênio / Terapia Trombolítica Idioma: En Ano de publicação: 1994 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Trombose Coronária / Ativadores de Plasminogênio / Terapia Trombolítica Idioma: En Ano de publicação: 1994 Tipo de documento: Article